Test Price
2,800 AED✅ Home Collection Available
GBA Gene Lewy Body Dementia Susceptibility Genetic Test, Dubai, UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
Diagnostic Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 Accredited NGS Processing (Cert: INT/EGQ/2509DA/3139). Our laboratory employs Next-Generation Sequencing with proprietary bioinformatics pipelines validated against international genomic reference databases, ensuring clinically actionable results for GBA variant classification in Lewy Body Dementia susceptibility assessment.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8:00 AM to 11:00 PM across all seven Emirates.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation provided by qualified genetic counselors, ensuring patients and referring physicians fully understand the clinical implications of identified GBA variants.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We interface with all major UAE health insurers for seamless pre-authorization.
Test Overview & Methodology
The GBA Gene Lewy Body Dementia Susceptibility Genetic Test is a comprehensive molecular diagnostic assay that analyzes the full coding sequence and splice-site regions of the GBA (glucosylceramidase beta) gene using Next-Generation Sequencing technology. Mutations in the GBA gene represent the most significant common genetic risk factor for Lewy Body Dementia (LBD), with heterozygous pathogenic variants conferring a 2- to 8-fold increased lifetime risk. This test is clinically indicated for individuals with a family history of LBD, Parkinson's disease, or Gaucher disease, as well as for patients presenting with prodromal symptoms including REM sleep behavior disorder, autonomic dysfunction, and fluctuating cognition.
Pre-Test Requirements & Specimen Logistics
Mandatory Pre-Test Genetic Counseling: A genetic counseling session is required prior to sample collection. This session will document a comprehensive three-generation pedigree chart identifying all family members affected with Lewy Body Dementia, Parkinson's disease, Gaucher disease, or related synucleinopathies. The counseling session also addresses the psychosocial implications of genetic susceptibility testing, including insurance considerations protected under UAE PDPL.
Specimen Matrix: Whole Blood (EDTA tube, 4 mL), Extracted DNA (minimum 2 µg at concentration ≥50 ng/µL, A260/A280 ratio 1.8–2.0), or Dried Blood Spot on FTA Card (one drop of whole blood, fully dried at room temperature for minimum 2 hours before packaging). Standard peripheral whole blood collection supports VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection.
| Parameter | Our Test — GBA NGS (DHA-Licensed) | Closest Alternative — Single-Gene Sanger Sequencing |
|---|---|---|
| Diagnostic Precision | Full Gene Coverage: All 11 exons, intron-exon boundaries, and deep intronic regulatory regions; CNV detection included | Limited to targeted exon-only amplification; CNV detection absent |
| Methodology | NGS (Next-Generation Sequencing) with 300x average read depth; validated against international genomic databases | Capillary Sanger Sequencing; lower sensitivity for mosaic variants (<20% allele fraction) |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Price (UAE) | 2800 AED | 1800 – 2500 AED (variable) |
| Regulatory Compliance | Full DHA-MOHAP Compliance; Federal Decree-Law No. 45 of 2021 (PDPL); ISO 9001:2015; Federal Law No. 2 of 2019 | Variable; may lack UAE-specific regulatory alignment |
Physician Insight & Safety Protocols
Clinical Note from Consultant Medical Genetics Lina Osama Zaki Quteineh (DHA Registration ID: 9294403) — "An identified GBA variant represents a susceptibility marker rather than a deterministic diagnosis of Lewy Body Dementia. This molecular finding must be integrated with a comprehensive neurological examination, neuropsychological assessment, and when clinically indicated, DAT-SPECT imaging to establish accurate clinical correlation. Genetic test results should never be interpreted in isolation; they constitute one component of a multifaceted diagnostic framework."
Advisory Notice
Medication Safety Advisory
Do not discontinue prescribed medication without consulting your doctor. Abrupt cessation of dopaminergic agents, cholinesterase inhibitors, or any centrally acting medications can precipitate acute decompensation. All medication adjustments must be supervised by your treating neurologist.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Home Collection:
- Individuals under 18 years of age — Minors require court-appointed guardian consent and specialized pediatric genetic counseling per Federal Law No. 2 of 2019
- Inability to provide informed consent due to advanced cognitive impairment (MoCA score <10) without a legally authorized representative
- Acute intercurrent illness with fever >38.5°C within 48 hours of scheduled collection
- Current anticoagulation therapy with INR >3.5 or platelets <50,000/µL (applies to venipuncture; FTA card collection remains available)
Emergency Red Flags — Seek Immediate Medical Attention:
- Acute onset of severe confusion, agitation, or hallucinations (may indicate delirium superimposed on dementia)
- Sudden deterioration in gait with recurrent falls and suspected subdural hematoma
- Neuroleptic malignant syndrome signs: hyperthermia, rigidity, elevated CK, and autonomic instability
- Suicidal ideation or psychotic features requiring emergency psychiatric intervention
Patient FAQ & Clinical Guidance
1. What exactly does the GBA gene test for Lewy Body Dementia detect, and how accurate is it?
The GBA NGS test detects pathogenic single-nucleotide variants, small insertions/deletions, and copy-number variations across all 11 exons of the GBA gene with 99.9% diagnostic sensitivity, identifying susceptibility mutations that increase lifetime risk for Lewy Body Dementia by 2- to 8-fold. This test does not diagnose active disease but stratifies genetic susceptibility. All variants are classified per ACMG/AMP guidelines using a five-tier system: Pathogenic, Likely Pathogenic, Variant of Uncertain Significance (VUS), Likely Benign, and Benign. VUS results are re-analyzed annually against updated population databases as part of our post-test stewardship program.
2. How is the test performed, and what should I expect during the sample collection process?
A certified phlebotomist collects a standard 4 mL EDTA whole blood sample from your arm during a 15-minute home visit, or alternatively a single finger-prick dried blood spot on an FTA card is obtained for patients with difficult venous access. Following the mandatory pre-test genetic counseling session (conducted via secure video consultation), our ISO-certified cold-chain logistics team arrives at your scheduled time. The sample is transported at 2–8°C to our DHA-licensed laboratory, where genomic DNA is extracted, quality-checked, and subjected to NGS library preparation. Sequencing runs on Illumina NovaSeq platforms achieve 300x average coverage depth across all GBA coding regions. Results are interpreted by board-certified molecular geneticists and delivered within 3 to 4 weeks via a secure, PDPL-compliant patient portal.
3. What do my GBA test results mean for my health and my family members?
A Pathogenic or Likely Pathogenic GBA variant confirms a significantly elevated genetic susceptibility to Lewy Body Dementia compared to the general population, necessitating longitudinal neurological surveillance, while a negative result does not eliminate the approximately 1.4% lifetime background risk inherent to all individuals. For family members, autosomal dominant inheritance with age-dependent penetrance means that each first-degree relative has a 50% chance of carrying the same variant; cascade testing is recommended for at-risk adult relatives. Importantly, GBA variant carriers may benefit from enrollment in ongoing clinical trials evaluating targeted therapies, including glucocerebrosidase chaperone molecules and substrate reduction agents. Our clinical team provides a comprehensive family risk assessment letter suitable for sharing with relatives and their healthcare providers.
UAE Regulatory & Data Privacy Adherence
✔ UAE Regulatory Compliance: This laboratory service is conducted under DHA Facility License No. 1143 and strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) governing genomic data privacy, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for digital health data security. All patient data is encrypted at rest and in transit, stored on sovereign UAE cloud infrastructure, and never shared with third parties without explicit informed consent. Clinical safety and patient consent protocols align with Federal Decree-Law No. 4 of 2016 on Medical Liability.
✔ ISO 9001:2015 Certified: Certificate No. INT/EGQ/2509DA/3139. Quality management system audited annually by an accredited certification body. Methodology validated against international genomic reference databases with continuous proficiency testing through EMQN (European Molecular Genetics Quality Network).
Clinical & Logistical Metadata
| Test Name | GBA Gene Lewy Body Dementia Susceptibility Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA, 4 mL), Extracted DNA (≥2 µg at ≥50 ng/µL), or Dried Blood Spot on FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq platform, 300x average read depth |
| ICD-10-CM Code | G31.83 |
| LOINC Code | 48018-6 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians